These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15670198)

  • 1. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
    Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
    Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience.
    Jalali R; Brada M; Perks JR; Warrington AP; Traish D; Burchell L; McNair H; Thomas DG; Robinson S; Johnston DG
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):695-702. PubMed ID: 10848873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma knife radiosurgery for acromegaly--long-term experience.
    Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
    Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes and mortality of 94 patients with acromegaly.
    Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
    Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
    Levitt NS; Ratanjee BD; Abrahamson MJ
    Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome.
    Langsenlehner T; Stiegler C; Quehenberger F; Feigl GC; Jakse G; Mokry M; Langsenlehner U; Kapp KS; Mayer R
    Strahlenther Onkol; 2007 May; 183(5):241-7. PubMed ID: 17497095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of radiotherapy for pituitary adenomas.
    Snead FE; Amdur RJ; Morris CG; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):994-8. PubMed ID: 18403133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.
    Resmini E; Barreca A; Ferone D; Giusti M; Sidoti M; Minuto F
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):294-7. PubMed ID: 16117816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
    Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
    Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study.
    Schalin-Jäntti C; Valanne L; Tenhunen M; Setälä K; Paetau A; Sane T; Kouri M
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):72-7. PubMed ID: 20039898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
    Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
    J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.